The results of many in vivo and/or in vitro studies have represented that activated MAPK/ERK1/2 signaling contributes to the initiation and progression of melanoma cancer by exacerbating drug resistance [72], distant tumor metastasis, or EMT [33]. Here, MAPK3 is linked to neoplasm.